Delivery of therapeutic protein for prevention of neurodegenerative changes: Comparison of different CSF-delivery methods

Experimental Neurology

Volumn 263, Issue , 2015, Pages 79-90

  Marshall, Neil R ^a   Hassiotis, Sofia ^b   King, Barbara ^b   Rozaklis, Tina ^b   Trim, Paul J ^b   Duplock, Stephen K ^b   Winner, Leanne K ^b   Beard, Helen ^b   Snel, Marten F ^b   Jolly, Robert D ^a   Hopwood, John J ^b   Hemsley, Kim M ^b  

^a MASSEY UNIVERSITY   (New Zealand)

^b SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Canine; Cerebrospinal fluid; Lysosomal storage disorder; Neurodegenerative disease; Recombinant protein; Treatment

Indexed keywords

GANGLIOSIDE; GLUTAMATE DECARBOXYLASE; RECOMBINANT PROTEIN; SULFAMIDASE; UNCLASSIFIED DRUG; HEPARAN SULFATE; HYDROLASE; N-SULFOGLUCOSAMINE SULFOHYDROLASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CEREBELLUM NUCLEUS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EFFICACY; ENZYME ACTIVITY; GLIOSIS; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; SANFILIPPO SYNDROME; ANIMAL; COMPARATIVE STUDY; DISEASE MODEL; DOG; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INTRASPINAL DRUG ADMINISTRATION; LIQUID CHROMATOGRAPHY; MUCOPOLYSACCHARIDOSIS; PATHOLOGY;

ANIMALS; CHROMATOGRAPHY, LIQUID; DISEASE MODELS, ANIMAL; DOGS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEPARITIN SULFATE; HUMANS; HYDROLASES; IMMUNOHISTOCHEMISTRY; INJECTIONS, SPINAL; MASS SPECTROMETRY; MUCOPOLYSACCHARIDOSES; RECOMBINANT PROTEINS;

EID: 84908011876     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2014.09.008     Document Type: Article

References (52)

1. Auclair D., Finnie J., White J., Nielsen T., Fuller M., Kakkis E., Cheng A., O'Neill C.A., Hopwood J.J. Repeated intrathecal injections of recombinant human 4-sulphatase remove dural storage in mature mucopolysaccharidosis VI cats primed with a short-course tolerisation regimen. Mol. Genet. Metab. 2010, 99:132-141.
2. Auclair D., Finnie J., Walkley S.U., White J., Nielsen T., Fuller M., Cheng A., O'Neill C.A., Hopwood J.J. Intrathecal recombinant human 4-sulfatase reduces accumulation of glycosaminoglycans in dura of mucopolysaccharidosis VI cats. Pediatr. Res. 2012, 71:39-45.
3. Auray-Blais C., Lavoie P., Zhang H., Gagnon R., Clarke J.T., Maranda B., Young S.P., An Y., Millington D.S. An improved method for glycosaminoglycan analysis by LC-MS/MS of urine samples collected on filter paper. Clin. Chim. Acta 2012, 413:771-778.
4. Bhaumik M., Muller V.J., Rozaklis T., Johnson L., Dobrenis K., Bhattacharyya R., Wurzelmann S., Finamore P., Hopwood J.J., Walkley S.U., et al. A mouse model for mucopolysaccharidosis type III A (Sanfilippo syndrome). Glycobiology 1999, 9:1389-1396.
5. Calias P., Papisov M., Pan J., Savioli N., Belov V., Huang Y., Lotterhand J., Alessandrini M., Liu N., Fischman A.J., et al. CNS penetration of intrathecal-lumbar idursulfase in the monkey, dog and mouse: implications for neurological outcomes of lysosomal storage disorder. PLoS One 2012, 7:e30341.
6. Ceuterick C., Martin J.J., Libert J., Farriaux J.P. Sanfilippo A disease in the fetus-comparison with pre- and postnatal cases. Neuropadiatrie 1980, 11:176-185.
7. Chang M., Cooper J.D., Sleat D.E., Cheng S.H., Dodge J.C., Passini M.A., Lobel P., Davidson B.L. Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis. Mol. Ther. 2008, 16:649-656.
8. Crawley A.C., Gliddon B.L., Auclair D., Brodie S.L., Hirte C., King B.M., Fuller M., Hemsley K.M., Hopwood J.J. Characterization of a C57BL/6 congenic mouse strain of mucopolysaccharidosis type IIIA. Brain Res. 2006, 1104:1-17.
9. Crawley A.C., Marshall N., Beard H., Hassiotis S., Walsh V., King B., Hucker N., Fuller M., Jolly R.D., Hopwood J.J., et al. Enzyme replacement reduces neuropathology in MPS IIIA dogs. Neurobiol. Dis. 2011, 43:422-434.
10. Dickson P., McEntee M., Vogler C., Le S., Levy B., Peinovich M., Hanson S., Passage M., Kakkis E. Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid. Mol. Genet. Metab. 2007, 91:61-68.
11. Dickson P.I., Hanson S., McEntee M.F., Vite C.H., Vogler C.A., Mlikotic A., Chen A.H., Ponder K.P., Haskins M.E., Tippin B.L., et al. Early versus late treatment of spinal cord compression with long-term intrathecal enzyme replacement therapy in canine mucopolysaccharidosis type I. Mol. Genet. Metab. 2010, 101:115-122.
12. Dickson I., Ellinwood N.M., Brown J.R., Witt R.G., Le S.Q., Passage M.B., Vera M.U., Crawford B.E. Specific antibody titer alters the effectiveness of intrathecal enzyme replacement therapy in canine mucopolysaccharidosis I. Mol. Genet. Metab. 2012, 106:68-72.
13. Dickson P.I., Chen A.H. Intrathecal enzyme replacement therapy for mucopolysaccharidosis I: translating success in animal models to patients. Curr. Pharm. Biotechnol. 2011, 12:946-955.
14. Dodge J.C., Clarke J., Treleaven C.M., Taksir T.V., Griffiths D.A., Yang W., Fidler J.A., Passini M.A., Karey K.P., Schuchman E.H., et al. Intracerebroventricular infusion of acid sphingomyelinase corrects CNS manifestations in a mouse model of Niemann-Pick A disease. Exp. Neurol. 2009, 215:349-357.
15. Folch J., Lees M., Sloane Stanley G.H. A simple method for the isolation and purification of total lipids from animal tissues. J. Biol. Chem. 1957, 226:497-509.
16. Fraldi A., Hemsley K., Crawley A., Lombardi A., Lau A., Sutherland L., Auricchio A., Ballabio A., Hopwood J. Functional correction of CNS lesions in a MPS-IIIA mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes. Hum. Mol. Genet. 2007, 16:2693-2702.
17. Gliddon B.L., Hopwood J.J. Enzyme-replacement therapy from birth delays the development of behavior and learning problems in mucopolysaccharidosis type IIIA mice. Pediatr. Res. 2004, 56:65-72.
18. Hassiotis S., Beard H., Luck A., Trim P., King B., Snel M., Hopwood J.J., Hemsley K.M. Disease stage determines the efficacy of treatment of a paediatric neurodegenerative disease. Eur. J. Neurosci. 2014, 39:2139-2150.
19. Hemsley K.M., King B., Hopwood J.J. Injection of recombinant human sulfamidase into the CSF via the cerebellomedullary cistern in MPS IIIA mice. Mol. Genet. Metab. 2007, 90:313-328.
20. Hemsley K.M., Beard H., King B.M., Hopwood J.J. Effect of high dose, repeated intra-CSF injection of sulphamidase on neuropathology in MPS IIIA mice. Genes Brain Behav. 2008, 7:740-753.
21. Hemsley K.M., Luck A.J., Crawley A.C., Hassiotis S., Beard H., King B., Rozek T., Rozaklis T., Fuller M., Hopwood J.J. Examination of intravenous and intra-CSF protein delivery for treatment of neurological disease. Eur. J. Neurosci. 2009, 29:1197-1214.
22. Hemsley K.M., Norman E.J., Crawley A.C., Auclair D., King B., Fuller M., Lang D.L., Dean C.J., Jolly R.D., Hopwood J.J. Effect of cisternal sulfamidase delivery in MPS IIIA Huntaway dogs-a proof of principle study. Mol. Genet. Metab. 2009, 98:383-392.
23. Hopwood J.J., Elliott H. Diagnosis of Sanfilippo type A syndrome by estimation of sulfamidase activity using a radiolabelled tetrasaccharide substrate. Clin. Chim. Acta 1982, 123:241-250.
24. Ikeda K., Shimizu T., Taguchi R. Targeted analysis of ganglioside and sulphatide molecular species by LC/ESI-MS/MS with theoretically expanded multiple reaction monitoring. J. Lipid Res. 2008, 49:2678-2689.
25. Jolly R.D., Allan F.J., Collett M.G., Rozaklis T., Muller V.J., Hopwood J.J. Mucopolysaccharidosis IIIA (Sanfilippo syndrome) in a New Zealand Huntaway dog with ataxia. N. Z. Vet. J. 2000, 48:144-148.
26. Jolly R.D., Marshall N.R., Perrott M.R., Dittmer K.E., Hemsley K.M., Beard H. Intracisternal enzyme replacement therapy in lysosomal storage diseases: routes of absorption into brain. Neuropathol. Appl. Neurobiol. 2011, 37:414-422.
27. Jolly R., Marshall N., Marshall J., Hartman A., Hemsley K., Winner L. Intracisternal enzyme replacement therapy in lysosomal storage diseases: dispersal pathways, regional enzyme concentrations and the effect of post-treatment posture. Neuropathol. Appl. Neurobiol. 2013, 39:681-692.
28. Kakkis E., McEntee M., Vogler C., Le S., Levy B., Belichenko P., Mobley W., Dickson P., Hanson S., Passage M. Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I. Mol. Genet. Metab. 2004, 83:163-174.
29. Kiatipattanasakul W., Nakayama H., Nakamura S., Doi K. Lectin histochemistry in the aged dog brain. Acta Neuropathol. 1998, 95:261-268.
30. Kondagari G.S., King B.M., Thomson P.C., Williamson P., Clements P.R., Fuller M., Hemsley K.M., Hopwood J.J., Taylor R.M. Treatment of canine fucosidosis by intracisternal enzyme infusion. Exp. Neurol. 2011, 230:218-226.
31. Lau A.A., Hemsley K.M., Meedeniya A., Hopwood J.J. In vitro characterization of genetically modified embryonic stem cells as a therapy for murine mucopolysaccharidosis type IIIA. Mol. Genet. Metab. 2004, 81:86-95.
32. Lau A.A., Hopwood J.J., Kremer E.J., Hemsley K.M. SGSH gene transfer in mucopolysaccharidosis type IIIA mice using canine adenovirus vectors. Mol. Genet. Metab. 2010, 100:168-175.
33. Lau A.A., Hannouche H., Rozaklis T., Hassiotis S., Hopwood J.J., Hemsley K.M. Allogeneic stem cell transplantation does not improve neurological deficits in mucopolysaccharidosis type IIIA mice. Exp. Neurol. 2010, 225:445-454.
34. Lee W.C., Tsoi Y.K., Troendle F.J., DeLucia M.W., Ahmed Z., Dicky C.A., Dickson D.W., Eckman C.B. Single-dose intracerebroventricular administration of galactocerebrosidase improves survival in a mouse model of globoid cell leukodystrophy. FASEB J. 2007, 21:2520-2527.
35. Malinowska M., Wilkinson F.L., Bennett W., Langford-Smith K.J., O'Leary H.A., Jakobkiewicz-Banecka J., Wynn R., Wraith J.E., Wegrzyn G., Bigger B.W. Genistein reduces lysosomal storage in peripheral tissues of mucopolysaccharide IIIB mice. Mol. Genet. Metab. 2009, 98:235-242.
36. Matsuoka K., Tamura T., Tsuji D., Dohzono Y., Kitakaze K., Ohno K., Saito S., Sakuraba H., Itoh K. Therapeutic potential of intracerebroventricular replacement of modified human beta-hexosaminidase B for GM2 gangliosidosis. Mol. Ther. 2011, 19:1017-1024.
37. McGlynn R., Dobrenis K., Walkley S.U. Differential subcellular localization of cholesterol, gangliosides, and glycosaminoglycans in murine models of mucopolysaccharide storage disorders. J. Comp. Neurol. 2004, 480:415-426.
38. Meikle P.J., Hopwood J.J., Clague A.E., Carey W.F. Prevalence of lysosomal storage disorders. JAMA 1999, 281:249-254.
39. Neufeld E.F., Muenzer J. The mucopolysaccharidoses. The Metabolic and Molecular Bases of Inherited Diseases 2001, 3421-3452. McGraw-Hill, New York, USA. C.R. Scriver (Ed.).
40. Roberts A.L., Rees M.H., Klebe S., Fletcher J.M., Byers S. Improvement in behaviour after substrate deprivation therapy with rhodamine B in a mouse model of MPS IIIA. Mol. Genet. Metab. 2007, 92:115-121.
41. Rozaklis T., Beard H., Hassiotis S., Garcia A.R., Tonini M., Luck A., Pan J., Lamsa J.C., Hopwood J.J., Hemsley K.M. Impact of high-dose, chemically modified sulfamidase on pathology in a murine model of MPS IIIA. Exp. Neurol. 2011, 230:123-130.
42. Ruzo A., Marcó S., García M., Villacampa P., Ribera A., Ayuso E., Maggioni L., Mingozzi F., Haurigot V., Bosch F. Correction of pathological accumulation of glycosaminoglycans in central nervous system and peripheral tissues of MPS IIIA mice through systemic AAV9 gene transfer. Hum. Gene Ther. 2012, 23:1237-1246.
43. Scott H.S., Blanch L., Guo X.H., Freeman C., Orsborn A., Baker E., Sutherland G.R., Morris C.P., Hopwood J.J. Cloning of the sulphamidase gene and identification of mutations in Sanfilippo A syndrome. Nat. Genet. 1995, 11:465-467.
44. Sorrentino N.C., D'Orsi L., Sambri I., Nusco E., Monaco C., Spampanato C., Polishchuk E., Saccone P., De Leonibus E., Ballabio A., et al. A highly secreted sulphamidase engineered to cross the blood-brain barrier corrects brain lesions of mice with mucopolysaccharidoses type IIIA. EMBO Mol. Med. 2013, 5:675-690.
45. Stroobants S., Gerlach D., Matthes F., Hartmann D., Fogh J., Gieselmann V., D'Hooge R., Matzner U. Intracerebroventricular enzyme infusion corrects central nervous system pathology and dysfunction in a mouse model of metachromatic leukodystrophy. Hum. Mol. Genet. 2011, 20:2760-2769.
46. Trim P.J., Lau A.A., Hopwood J.J., Snel M.F. A simple method for early age phenotype confirmation using toe tissue from a mouse model of MPS IIIA. Rapid Commun. Mass Spectrom. 2014, 28:933-938.
47. Tsuji D., Akeboshi H., Matsuoka K., Yasuoka H., Miyasaki E., Kasahara Y., Kawashima I., Chiba Y., Jigami Y., Taki T., et al. Highly phosphomannosylated enzyme replacement therapy for GM2 gangliosidosis. Ann. Neurol. 2010, 69:691-701.
48. Valstar M.J., Neijs S., Bruggenwirth H.T., Olmer R., Ruijter G.J., Wevers R.A., van Diggelen O.P., Poorthuis B.J., Halley D.J., Wijburg F.A. Mucopolysaccharidosis type IIIA: clinical spectrum and genotype-phenotype correlations. Ann. Neurol. 2010, 68:876-887.
49. Vite C.H., Wang P., Patel R.T., Walton R.M., Walkley S.U., Sellers R.S., Ellinwood N.M., Cheng A.S., White J.T., O'Neill C.A., et al. Biodistribution and pharmacodynamics of recombinant human alpha-L-iduronidase (rhIDU) in mucopolysaccharidosis type I-affected cats following multiple intrathecal administrations. Mol. Genet. Metab. 2011, 103:268-274.
50. Wilsson-Rahmberg M., Olovson S.G., Forshult E. Method for long-term cerebrospinal fluid collection in the conscious dog. J. Investig. Surg. 1998, 11:207-214.
51. Yang W.W., Dodge J.C., Passini M.A., Taksir T.V., Griffiths D., Schuchman E.H., Cheng S.H., Shihabuddin L.S. Intraparenchymal injections of acid sphingomyelinase results in regional correction of lysosomal storage pathology in the Niemann-Pick A mouse. Exp. Neurol. 2007, 207:258-626.
52. Yogalingam G., Pollard T., Gliddon B., Jolly R.D., Hopwood J.J. Identification of a mutation causing mucopolysaccharidosis type IIIA in New Zealand Huntaway dogs. Genomics 2002, 79:150-153.